JP4488351B2 - 可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡＩＸ）、ｓ−ＣＡＩＸを検出するためのアッセイ、ＣＡＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡＩＸ特異的モノクローナル抗体 - Google Patents

可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡＩＸ）、ｓ−ＣＡＩＸを検出するためのアッセイ、ＣＡＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡＩＸ特異的モノクローナル抗体 Download PDF

Info

Publication number
JP4488351B2
JP4488351B2 JP2004508271A JP2004508271A JP4488351B2 JP 4488351 B2 JP4488351 B2 JP 4488351B2 JP 2004508271 A JP2004508271 A JP 2004508271A JP 2004508271 A JP2004508271 A JP 2004508271A JP 4488351 B2 JP4488351 B2 JP 4488351B2
Authority
JP
Japan
Prior art keywords
antibody
protein
cells
antibodies
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004508271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535601A (ja
JP2005535601A5 (ja
Inventor
パストレック，ヤロミール
パストレコヴァ，シルヴィア
ザトヴィコヴァ，ミリアム
ザヴァダ，ヤン
グト，マルタ オルトヴァ
ザヴァドヴァ，ズザンナ
Original Assignee
インスティトゥート オブ ヴァイロロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスティトゥート オブ ヴァイロロジー filed Critical インスティトゥート オブ ヴァイロロジー
Priority claimed from PCT/US2003/005136 external-priority patent/WO2003100029A2/en
Publication of JP2005535601A publication Critical patent/JP2005535601A/ja
Publication of JP2005535601A5 publication Critical patent/JP2005535601A5/ja
Application granted granted Critical
Publication of JP4488351B2 publication Critical patent/JP4488351B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2004508271A 2002-02-21 2003-02-21 可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡＩＸ）、ｓ−ＣＡＩＸを検出するためのアッセイ、ＣＡＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡＩＸ特異的モノクローナル抗体 Expired - Fee Related JP4488351B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35882402P 2002-02-21 2002-02-21
US38306802P 2002-05-23 2002-05-23
US43149902P 2002-12-05 2002-12-05
PCT/US2003/005136 WO2003100029A2 (en) 2002-02-21 2003-02-21 Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2008325146A Division JP4514820B2 (ja) 2002-02-21 2008-12-22 可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡ ＩＸ）、ｓ−ＣＡ ＩＸを検出するためのアッセイ、ＣＡ ＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡ ＩＸ特異的モノクローナル抗体
JP2009288124A Division JP5199228B2 (ja) 2002-02-21 2009-12-18 可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡＩＸ）、ｓ−ＣＡＩＸを検出するためのアッセイ、ＣＡＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡＩＸ特異的モノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2005535601A JP2005535601A (ja) 2005-11-24
JP2005535601A5 JP2005535601A5 (ja) 2006-01-12
JP4488351B2 true JP4488351B2 (ja) 2010-06-23

Family

ID=33425052

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2004508271A Expired - Fee Related JP4488351B2 (ja) 2002-02-21 2003-02-21 可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡＩＸ）、ｓ−ＣＡＩＸを検出するためのアッセイ、ＣＡＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡＩＸ特異的モノクローナル抗体
JP2008325146A Expired - Fee Related JP4514820B2 (ja) 2002-02-21 2008-12-22 可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡ ＩＸ）、ｓ−ＣＡ ＩＸを検出するためのアッセイ、ＣＡ ＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡ ＩＸ特異的モノクローナル抗体
JP2009288124A Expired - Fee Related JP5199228B2 (ja) 2002-02-21 2009-12-18 可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡＩＸ）、ｓ−ＣＡＩＸを検出するためのアッセイ、ＣＡＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡＩＸ特異的モノクローナル抗体
JP2012248466A Expired - Fee Related JP5271443B2 (ja) 2002-02-21 2012-11-12 可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡＩＸ）、ｓ−ＣＡＩＸを検出するためのアッセイ、ＣＡＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡＩＸ特異的モノクローナル抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2008325146A Expired - Fee Related JP4514820B2 (ja) 2002-02-21 2008-12-22 可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡ ＩＸ）、ｓ−ＣＡ ＩＸを検出するためのアッセイ、ＣＡ ＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡ ＩＸ特異的モノクローナル抗体
JP2009288124A Expired - Fee Related JP5199228B2 (ja) 2002-02-21 2009-12-18 可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡＩＸ）、ｓ−ＣＡＩＸを検出するためのアッセイ、ＣＡＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡＩＸ特異的モノクローナル抗体
JP2012248466A Expired - Fee Related JP5271443B2 (ja) 2002-02-21 2012-11-12 可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡＩＸ）、ｓ−ＣＡＩＸを検出するためのアッセイ、ＣＡＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡＩＸ特異的モノクローナル抗体

Country Status (8)

Country Link
US (5) US7846673B2 (https=)
EP (1) EP1487972B1 (https=)
JP (4) JP4488351B2 (https=)
AU (1) AU2003217606C1 (https=)
CA (1) CA2477163C (https=)
DK (2) DK3031910T3 (https=)
HU (3) HUE026218T2 (https=)
WO (1) WO2004005348A1 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508596B1 (en) * 2002-02-21 2015-08-12 Institute Of Virology MN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
DK3031910T3 (en) * 2002-02-21 2017-10-23 Inst Virology MN / CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED BY MN / CA IX-DEFICIENT MOUSE AND METHODS OF USE
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
EP1501939B1 (en) * 2002-04-16 2009-07-22 The Regents of The University of California Methods or renal cell carcinoma prognosis and treatment selection with carbonic anhydrase ix
US20090239247A1 (en) * 2002-12-13 2009-09-24 Harris Adrian L MN and Hypoxia
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
EP2837697B1 (en) * 2006-10-10 2016-12-07 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection methods based on those alternations
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
EP2219668A1 (en) * 2007-11-02 2010-08-25 Wilex AG Binding epitopes for g250 antibody
CN101868445B (zh) 2007-11-19 2014-06-18 旭化成化学株式会社 异氰酸酯和芳香族羟基化合物的制造方法
ES2890501T3 (es) 2009-03-02 2022-01-20 Massachusetts Inst Technology Métodos y productos para la creación de perfiles enzimáticos in vivo
EP2295975B1 (en) * 2009-09-10 2014-06-18 Bruker Daltonik GmbH Determining the expression status of human epidermal growth factor receptor 2 (HER2) in biological samples
CA2830235C (en) 2011-03-15 2023-10-24 Massachusetts Institute Of Technology Multiplexed detection with isotope-coded reporters
US9080849B2 (en) 2011-07-29 2015-07-14 Milwaukee Electric Tool Corporation Tape measure
CA2784047C (en) 2011-07-29 2015-08-11 Milwaukee Electric Tool Corporation Tape measure
US8863399B2 (en) 2011-08-26 2014-10-21 Milwaukee Electric Tool Corporation Tape measure
EP2508890A1 (en) * 2011-10-25 2012-10-10 Roche Diagnostics GmbH CAIX based diagnosis of heart failure
WO2013096687A1 (en) 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
US9267778B2 (en) 2012-01-19 2016-02-23 Milwaukee Electric Tool Corporation Tape measure
EP2810076A4 (en) * 2012-01-31 2015-07-01 Threshold Pharmaceuticals Inc PRÄDIKTIVER BIOMARKER FOR HYPOXIA-ACTIVATED PRODRUGTHERAPY
JP2015155795A (ja) * 2012-05-21 2015-08-27 東レ株式会社 癌の検出方法
USD733597S1 (en) 2012-07-30 2015-07-07 Milwaukee Electric Tool Corporation Tape measure
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
JP6847660B2 (ja) * 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
EP3286337A4 (en) * 2015-04-23 2018-12-12 Cedars-Sinai Medical Center Automated delineation of nuclei for three dimensional (3-d) high content screening
USD785476S1 (en) 2015-12-10 2017-05-02 Milwaukee Electric Tool Corporation Tape measure
USD785475S1 (en) 2015-12-10 2017-05-02 Milwaukee Electric Tool Corporation Tape measure
USD783429S1 (en) 2016-01-07 2017-04-11 Milwaukee Electric Tool Corporation Tape measure
USD783430S1 (en) 2016-01-07 2017-04-11 Milwaukee Electric Tool Corporation Tape measure
USD787347S1 (en) 2016-01-07 2017-05-23 Milwaukee Electric Tool Corporation Tape measure
WO2017177115A1 (en) 2016-04-08 2017-10-12 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
US11428689B2 (en) 2016-05-05 2022-08-30 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
USD788611S1 (en) 2016-06-01 2017-06-06 Milwaukee Electric Tool Corporation Tape measure
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
CA3059358A1 (en) 2017-04-07 2018-10-11 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
WO2018197893A1 (en) 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
US11054428B2 (en) 2018-03-05 2021-07-06 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US11732009B2 (en) 2018-06-08 2023-08-22 Glympse Bio, Inc. Activity sensor with tunable analyte
US11028425B2 (en) 2018-06-08 2021-06-08 Glympse Bio, Inc. Diagnosis and monitoring of liver disease
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
EP3856921B1 (en) 2018-09-25 2026-04-29 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
WO2020150560A1 (en) 2019-01-17 2020-07-23 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
JP7740987B2 (ja) 2019-02-28 2025-09-17 ジョージア・テック・リサーチ・コーポレーション 生物学的活性の論理ゲート化プロファイリングのための組成物および方法
WO2020226612A1 (en) * 2019-05-06 2020-11-12 Navi Bio-Therapeutics, Llc Anti-carbonic anhydrase ix antibody
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
MX2022005332A (es) * 2019-11-05 2022-05-26 Mabpro A S Anticuerpos anti-ca ix humanizados y metodos de su uso.
CN111273036B (zh) * 2020-03-06 2021-06-15 中国农业科学院兰州兽医研究所 检测口蹄疫非结构蛋白抗体的单抗竞争化学发光试剂盒
IL300248A (en) 2020-08-03 2023-03-01 Bicycletx Ltd peptide-based linkers
EP4211468A4 (en) 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
CN116167592B (zh) * 2023-04-20 2023-06-23 交通运输部天津水运工程科学研究所 一种河流溢油风险防控和决策支持系统

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US6204370B1 (en) 1992-03-11 2001-03-20 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5989838A (en) 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US6774117B1 (en) 1992-03-11 2004-08-10 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6027887A (en) 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US6093548A (en) 1992-03-11 2000-07-25 Institute Of Virology, Slovak Academy Of Sciences Detection and quantitation of MN-specific antibodies.
US5981711A (en) 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US6297051B1 (en) 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6069242A (en) 1992-03-11 2000-05-30 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297041B1 (en) * 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5972353A (en) 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides
US5955075A (en) 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
CA2192678C (en) * 1994-06-15 2010-12-14 Jan Zavada Mn gene and protein
US6451977B1 (en) * 1998-02-26 2002-09-17 Genentech, Inc. Fused polypeptides
JP3910798B2 (ja) 1998-10-23 2007-04-25 インスティトゥート オブ ヴァイロロジー Ｍｎ遺伝子およびタンパク質
AU2002351208A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
DK3031910T3 (en) * 2002-02-21 2017-10-23 Inst Virology MN / CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED BY MN / CA IX-DEFICIENT MOUSE AND METHODS OF USE
EP1576010A4 (en) 2002-08-23 2006-12-27 Chiron Corp THERAPEUTIC COMPOSITIONS AND METHODS FOR CANCER CHARACTERIZED BY EXPRESSION OF MN / CA IX ANTIGEN ASSOCIATED WITH TUMORS
WO2008103327A2 (en) 2007-02-20 2008-08-28 Bayer Pharmaceuticals Corporation Mn/ca ix and bladder cancer
EP2219668A1 (en) * 2007-11-02 2010-08-25 Wilex AG Binding epitopes for g250 antibody

Also Published As

Publication number Publication date
DK3031910T3 (en) 2017-10-23
US7816493B2 (en) 2010-10-19
US7846673B2 (en) 2010-12-07
HUE026218T2 (en) 2016-05-30
JP2013060452A (ja) 2013-04-04
HUE036891T2 (hu) 2018-08-28
AU2003217606B2 (en) 2007-11-22
JP2010111679A (ja) 2010-05-20
US20080176258A1 (en) 2008-07-24
US20050031623A1 (en) 2005-02-10
HK1226095B (en) 2017-09-22
WO2004005348A1 (en) 2004-01-15
JP2009114198A (ja) 2009-05-28
AU2003217606A2 (en) 2003-12-12
JP5199228B2 (ja) 2013-05-15
US20150266971A1 (en) 2015-09-24
JP4514820B2 (ja) 2010-07-28
JP2005535601A (ja) 2005-11-24
HUE026277T2 (en) 2016-05-30
US20080176310A1 (en) 2008-07-24
CA2477163A1 (en) 2003-12-04
EP1487972A2 (en) 2004-12-22
JP5271443B2 (ja) 2013-08-21
US7833728B2 (en) 2010-11-16
DK1487972T3 (en) 2015-10-19
AU2003217606A1 (en) 2003-12-12
US20080177046A1 (en) 2008-07-24
EP1487972A4 (en) 2006-05-31
EP1487972B1 (en) 2015-08-12
AU2003217606B8 (en) 2003-12-12
HK1177474A1 (en) 2013-08-23
AU2003217606C1 (en) 2008-07-17
CA2477163C (en) 2010-07-27

Similar Documents

Publication Publication Date Title
JP4488351B2 (ja) 可溶型の炭酸脱水酵素ＩＸ（ｓ−ＣＡＩＸ）、ｓ−ＣＡＩＸを検出するためのアッセイ、ＣＡＩＸとＨＥＲ−２／ｎｅｕ／ｃ−ｅｒｂＢ−２の同時発現、非免疫優性エピトープに対するＣＡＩＸ特異的モノクローナル抗体
RU2715038C2 (ru) Антитела анти-pd-l1 и способы их диагностического применения
KR101560843B1 (ko) 페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
JP2003523207A (ja) Ｌｉｖ−１関連タンパク質、それをコードするポリヌクレオチド、及び癌の治療へのその利用
WO2003100029A2 (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
US20080241066A1 (en) Anti-PRL-3 antibodies and methods of use thereof
EP2508596B1 (en) MN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
AU2008200868B2 (en) Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX's coexpression with HER-2/neu/c-erb-B2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes
HK1226095A1 (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
HK1177474B (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081029

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090610

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091218

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20091218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100223

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100325

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130409

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130409

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140409

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees